Respiri Limited (ASX: RSH)


Respiri Limited (ASX: RSH) is a technologically focused medical device company offering products to the respiratory health segment. www.respiri.co

Respiri Pharmacy 4 Less wheezo ASX RSH

Respiri teams up with Pharmacy 4 Less group for wheezo sales

Respiratory health technology company Respiri (ASX: RSH) has announced a new sales and marketing partnership with the Pharmacy 4 Less group for ...
Respiri Cipla wheezo ASX RSH orders demand brand partnership

Respiri orders up on growing demand for wheezo device, announces new brand partnership

Demand for Respiri’s (ASX: RSH) wheezo asthma management device has continued to grow following the platform’s recent commercial launch in Austr...
Respiri wheezo Carlton Football Club game changers AFLW AFL logo

Respiri’s wheezo logo scores prime position on Carlton AFLW uniforms

Three months after announcing the start of a co-major partnership with Carlton Football Club, health technology developer Respiri (ASX: RSH) has...
Respiri RSH ASX costs wheezo technology Australian pharmacies manufacturing

Respiri shaves costs as wheezo technology continues to be well-received

With Respiri’s (ASX: RSH) stage launch of wheezo across select Australian pharmacies and online underway, the company has revealed further major...
Respiri ASX RSH wheezo launch Cipla pharmacists

Respiri ‘pleased’ with wheezo feedback from initial sales and marketing

Respiratory health management company Respiri (ASX: RSH) has updated the market regarding the preliminary release of its wheezo platform and dev...
Respiri ASX RSH patent application wheezo asthma management device

Respiri files new patent application for wheezo asthma management device

Respiratory-focused eHealth company Respiri (ASX: RSH) has filed an additional patent application based on recent improvements made to the algor...
Respiri raises placement commercialise wheezo asthma device ASX RSH

Respiri raises $12.5 million to commercialise wheezo asthma device

eHealth company Respiri (ASX: RSH) has completed a $12.5 million capital raising targeted at the commercial launch of its proprietary wheezo ast...
Respiri ASX RSH Entech Electronics wheezo

Respiri engages Entech Electronics to manufacture wheezo at ‘significantly’ improved cost

Health technology company Respiri (ASX: RSH) has engaged Entech Electronics to manufacture its “ground breaking” wheezo device offshore in China...
Respiri wheezo clinical study results ASX RSH 2020

Respiri unveils promising wheezo clinical study results

Preliminary results of a clinical study involving the wheezo asthma management platform made by eHealth technology developer Respiri (ASX: RSH) ...
Respiri ASX RSH Carlton Football Club AFLW Team womens wheezo

Respiri teams up with Carlton Football Club to promote wheezo device

A day after publishing its full year accounts, eHealth company Respiri (ASX: RSH) has tentatively set foot in Australian rules football courtesy...
Respiri ASX RSH Australian Patients Association APA asthma wheezo

Respiri signs referral agreement with APA to proliferate wheezo in Australia

eHealth company Respiri (ASX: RSH) has taken another step towards growing sales of its wheezo device ahead of its October launch, after signing ...
Respiri ASX RSH Australian Patients Association wheezo real world study

Respiri partners with Australian Patients Association for wheezo study

eHealth Software-as-a-Service (Saas) company Respiri (ASX: RSH) has updated the market with news it has entered into a partnership with the Aust...
Respiri ASX RSH wheezo revenue 2021 Software as a Service SaaS

eHealth SaaS provider Respiri targets $6-8m revenue for 2021

eHealth technology developer and maker of the wheezo device, Respiri (ASX: RSH) has published interim revenue guidance for 2021 with total reven...
Respiri ASX RSH wheezo BNPL Zip

Respiri accelerates wheezo commercialisation by teaming up with BNPL company Zip

Wheezo developer Respiri’s (ASX: RSH) commercialisation path will accelerate even further after the company collared a deal with renowned buy no...
Respiri Wheezo ASX RSH sales distribution Cipla Australia

Respiri secures global sales and distribution agreement for wheezo asthma monitoring device

Healthcare technology developer Respiri (ASX: RSH) has signed an exclusive agreement with global respiratory pharmaceutical firm Cipla for the s...
Respiri eHealth SaaS Company Wheezo Health Data Research Hub for Respiratory Health HDR UK ASX RSH

Respiri partners with UK data research centre in preparation for Wheezo’s EU launch

eHealth software company Respiri (ASX: RSH) has unveiled a new partnership agreement with the University of Edinburgh to feed data from its prop...
Respiri ASX RSH wheezo Pharmacy Guild of Australia market potential agreement

Respiri grows wheezo market potential through agreement with the Pharmacy Guild of Australia

Respiri (ASX: RSH) has collared a two-year definitive service agreement with the Pharmacy Guild of Australia to develop an online pharmacist cou...
Respiri Share Purchase Plan SPP ASX RSH Wheezo

Shareholders back Respiri in heavily oversubscribed share purchase plan

Respiri (ASX: RSH) has topped up its cash reserves with $3.14 million after receiving “significant oversubscriptions” in a recent share purchase...
Respiri telehealth GPNow ASX RSH Practice Innovators International respiratory asthma

Respiri strikes telehealth deal with Aussie start-up to improve respiratory care for asthma patients

Respiratory health management company Respiri (ASX: RSH) has entered into commercial discussions with Australian start-up Practice Innovators In...
Respiri wheezo telehealth market Phenix Health ASX RSH

Respiri expands wheezo into telehealth market with Phenix partnership

Respiri (ASX: RSH) has expanded the market for its wheezo technology after announcing a partnership with Phenix Health. The parties have inke...
Respiri coronavirus COVID19 China Wheezo ASX RSH

Respiri experiences requests for wheezo devices to monitor COVID-19 patients in China

Respiratory focused SaaS company Respiri (ASX: RSH) has experienced inbound demand for its wheezo technology from three Chinese hospitals ...